✦ LIBER ✦

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients

✍ Scribed by Bümming, P; Andersson, J; Meis-Kindblom, J M; Klingenstierna, H; Engström, K; Stierner, U; Wängberg, B; Jansson, S; Ahlman, H; Kindblom, L-G

Book ID: 109997583
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 219 KB
Volume: 89
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6600965

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN38 NUMBER NEEDED TO TREAT (NNT) TO AV

PCN38 NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF ADJUVANT TREATMENT WITH IMATINIB

✍ J Valentim; J Coombs; A Sakano; F Puty 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Adjuvant Imatinib treatment after R0 res

Adjuvant Imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: A median follow-up of 44 months

✍ Wei-Zhong Jiang; Guo-Xian Guan; Hui-Shan Lu; Ying-Hong Yang; De-Yong Kang; He-Gu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

A long-term follow-up of the imatinib me

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome

✍ Jiang Zhu; Yu Yang; Lin Zhou; Ming Jiang; Mei Hou 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 641 KB

Predicting toxicities for patients with

Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: A study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC–ISG–AGITG)

✍ Martine Van Glabbeke; Jaap Verweij; Paolo G. Casali; John Simes; Axel Le Cesne; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 187 KB